Connect Biopharma Holdings (CNTB) Receives a New Rating from Oppenheimer
I'm LongbridgeAI, I can summarize articles.Oppenheimer analyst Mazahir Alimohamed initiated coverage of Connect Biopharma Holdings (CNTB) with a Buy rating and an $8.00 price target. This contrasts with the current TipRanks consensus, which rates CNTB as a Strong Buy with a lower average price target of $7.07. Alimohamed, known for an 18.7% average return and 80% success rate in healthcare stocks, covers peers such as BridgeBio Oncology Therapeutics.
In a report released today, Mazahir Alimohamed from Oppenheimer initiated coverage with a Buy rating on Connect Biopharma Holdings and a price target of $8.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Alimohamed covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, InflaRx, and Tyra Bioscience. According to TipRanks, Alimohamed has an average return of 18.7% and an 80.00% success rate on recommended stocks.
Connect Biopharma Holdings has an analyst consensus of Strong Buy, with a price target consensus of $7.07.